GNPX

Genprex is a clinical-stage gene-therapy company with zero product revenue across every year shown (FY2021–FY2024 all $0.00) and no path to it until REQORSA or GPX-002 clears years of trials. Its value is entirely the option on a lead candidate still in the Phase 2a expansion of a Phase 1/2 study (Acclaim-1, REQORSA + Tagrisso in EGFR NSCLC). The FY2025 loss narrowed to -$16.2M (from -$21.1M) and operating loss improved 26.7%, but that 'improvement' is cost-cutting — R&D actually fell 10.5% to $9.43M — not progress, and a -203.8% ROE with a -$171M accumulated deficit shows how much capital this platform has already consumed for nothing bankable.

The balance sheet is the disqualifier. Cash is just $7.83M against ~$15.3M of annual operating cash burn. Management's own language says existing cash funds operations only 'into the second quarter of 2027' and explicitly states 'our existing capital will not be sufficient to enable us to complete the development' — they will require 'substantial additional funding, which may not be available to us on acceptable terms, or at all.' The 62.6% collapse in shares outstanding to 9.04M signals a reverse split to stay listed, and the equity/cash surge (+391%/+389%) is fresh raised capital, not operations — meaning shareholders have already been, and will keep being, diluted to keep the lights on. The filing also flags identified material weaknesses in internal controls.